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INTRODUCTION
Adenoid cystic carcinoma (ACC) is a locally aggressive sali-
vary gland neoplasm characterized by its long clinical history 
with multiple recurrences and late distant metastasis.1 Distant 
metastasis can develop over more than 10 years after the ini-
tial treatment, and 10-year survival has been shown to de-
crease by 30% in ACC patients with distant metastasis. Distant 
metastasis has often been associated with advanced stage tu-
mors, although one study reported occurrence of distant me-
tastasis in 47% of patients with early stage ACC, suggesting 
that distant metastasis can readily occur in ACC patients re-
gardless of the tumor stage.2 
One of the main oncogenic drivers of ACC is the tumor type-
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Purpose: Adenoid cystic carcinoma (ACC) is a high-grade malignant tumor of the salivary glands, clinically characterized by mul-
tiple recurrences and late distant metastasis. Biological markers for assessing the prognosis of ACC have remained elusive. The 
purpose of this study was to investigate whether the protein expressions of ataxia telangiectasia mutated (ATM), p53, and ATM-
mediated phosphorylated p53 are related to patient survival in ACC. 
Materials and Methods: In this study, 48 surgical samples were used to assess the expressions of ATM and its downstream target 
p53. Fisher’s exact test and Kaplan-Meier analysis were conducted to evaluate the role of ATM, p53, and phospho-p53 (S15) pro-
tein expressions in predicting patient survival and distant metastasis. 
Results: Myb expression was positive in 85.4% of ACCs, but did not reflect patient survival rate. In contrast, low expression of ATM 
in cancer cells was significantly correlated with poor survival rate (p=0.037). Moreover, under positive p53 expression, low expres-
sion of ATM was highly predictive of poor survival in ACC (p=0.017). 
Conclusion: These data indicate that combined assessment of ATM and p53 expression can serve as a useful prognostic marker 
for assessing survival rate in patients with ACC of the salivary glands.
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specific chromosomal translocation t(6;9) (q22–23;p23–24) 
resulting in Myb-NFIB fusion oncogene. Myb-NFIB fusion con-
tributes to Myb overexpression and activation of critical Myb 
target genes, including those associated with apoptosis, cell 
cycle control, cell growth, angiogenesis, and cell adhesion.3 Re-
cent studies in surgical pathology have shown that overex-
pression of Myb occurs in most ACCs (89%), including ACCs 
without Myb-NFIB fusion, suggesting Myb expression as a 
useful marker for ACC.4,5 Despite Myb activation being an im-
portant diagnostic marker of ACC, its value as a prognostic 
marker was rather limited.3 
Ataxia telangiectasia mutated (ATM) is a 370-kd protein be-
longing to a family of phosphoinositide 3-kinases with roles in 
DNA processing, regulation of the cell cycle, and control of 
telomere length. The principal function of ATM is the integra-
tion of cellular responses to DNA double-strand breaks.6 Ho-
mozygous mutation of the ATM gene results in the loss of de-
tectable protein, triggering ataxia-telangiectasia (A-T),7 an 
autosomal recessive disorder characterized by neurological 
and immunological symptoms, radiosensitivity, and predispo-
sition to cancer, particularly of the lymphoid system.8,9 Accu-
mulating evidence indicates that A-T heterozygotes also have 
increased risk of developing cancer, breast cancer in particu-
lar, for which female ATM carriers have increased risk, com-
pared with the general population.10 Intriguingly, a recent study 
demonstrated that ATM expression in cancer-associated stro-
ma, as well as cancer cells, can serve as an independent prog-
nostic marker in early stage breast cancer.11 Loss of ATM expres-
sion has also been associated with poor prognosis in pancreatic 
cancer and gastric cancer.12,13 
As a downstream target protein of ATM, p53 is recognized as 
the most common tumor suppressor in human malignancies. 
The mutational status of p53 is an independent unfavorable 
prognostic marker in many malignancies.14 Due to the lack of 
biological markers for assessing the prognosis of ACC patients, 
this study attempted to investigate the role of ATM and p53 ex-
pressions in predicting the survival of ACC patients. The prog-
nostic biomarkers obtained in this study will likely facilitate 
more accurate assessment of ACC patients, thereby allowing 




This study included 48 surgical samples identified as ACC of 
the salivary glands at the Department of Oral Pathology, Den-
tal Hospital, Yonsei University from 1990–2015. This study was 
approved by the Institutional Review Board of the Faculty of 
Dental Sciences, Yonsei University, South Korea (2-2015-0031). 
The clinical information of all patients was collected retrospec-
tively through medical records (Table 1). All cases were con-








Woman 23 (47.9) 18 (78.3)
Man 25 (52.1) 23 (92)
Age (yr) 0.403
<55 26 (54.2) 23 (88.5)
≥55 22 (45.8) 14 (63.6)
Tumor site 0.523
Parotid gland   3 (6.3)   3 (100)
Submandibular gland   8 (16.7)   5 (62.5)
Sublingual gland   1 (2.1)   1 (100)
Palate 23 (47.9) 17 (73.9)
Upper lip   2 (4.2)   1 (50)
Lower lip   1 (2.1)   1 (100)
Tongue   2 (4.2)   1 (100)
Buccal   1 (2.1)   0 (0)
Retromolar area   1 (2.1)   0 (0)
Floor of mouth   6 (12.5)   5 (83.3)
Histology 0.011
Solid 13 (27.1)   8 (61.5)
Tubular and cribriform 35 (72.9) 33 (94.3)
Perineural invasion 29 (60.4) 21 (72.4) 0.739
Total no. of patients 48 (100) 41 (85.4)  
p values from Fisher’s exact test are provided.
firmed histologically in accordance with the guidelines of the 
latest World Health Organization classification of salivary 
gland tumors, based on hematoxylin and eosin-stained tissue 
sections.15 There was no age, sex, ethnicity, or tumor stage re-
striction on patient enrollment. Follow-up was calculated as the 
time from the first visitation at the institution for the primary 
tumor to the latest follow-up or deceased date. 
Immunohistochemical staining 
The staining was performed on 4-μm-thick sections using an 
EnVision-HRP detection system (Dako, Carpinteria, CA, USA). 
All procedures were performed at room temperature. Sections 
were deparaffinized through a series of xylene baths and re-
hydrated in graded concentrations of alcohol. To retrieve anti-
genicity, the slides were steamed with 10 mmol/L of citrate 
buffer (pH 6.0; DakoREALTM). Tissue sections were treated 
with 3% hydrogen peroxide to block endogenous peroxidase 
activity, followed by incubation in 5% bovine serum albumin. 
The sections were then incubated with primary antibodies di-
luted with phosphate buffered saline for 90 min in a humid 
chamber. All information on primary antibodies is listed on 
Supplementary Table 1 (only online). The slides were then in-
cubated with secondary EnVision reagent (Dako) for 30 min, 
followed by incubation with diaminobenzidine chromogen. 
Next, the sections were counterstained with Mayer hematoxy-
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lin for visualization. The phosphate-buffered saline solution 
without primary antibody treatment was applied as the nega-
tive control for all antibody staining. Human lymphocytes and 
normal salivary glands were used as positive controls for ATM 
staining as recommended by Villaruz, et al.16 A paraffin-em-
bedded breast cancer cell line was used to determine appro-
priate dilution ratio and as a positive control for p53 and phos-
pho-p53 (S15). 
With a cutoff of >25% positive cells, positivity of nuclear Myb 
expression was determined according to previously reported 
guidelines,17 whereas “loss of ATM expression” was determined 
as tumors showing >25% ATM-negative cells.18 Because mu-
tant p53 proteins generally have longer half-lives than wild-
type p53 protein, which leads to their nuclear accumulation, 
tumors showing >20% nuclear p53 or phospho-p53 (S15)-
positive tumor cells were determined as having positive p53 
or phospho-p53 (S15) expression.19 
Statistical analysis
Correlation between clinical findings and patient survival was 
analyzed by Fisher’s exact test. Cumulative survival probabili-
ties were estimated using the Kaplan-Meier method. All statisti-
cal analyses were performed using statistical software (SPSS 
version 21.0, IBM Corp., Armonk, NY, USA), and the level of 
statistical significance was set at p<0.05. 
Table 2. Clinico-Pathological Characteristics of Patients Showing Poor Prognosis 
Parameter
No. of patients (%)
Recurrence Distant metastasis Death due to ACC
Sex
Woman -   8 (44.4) 3 (60)
Man 2 (100) 10 (55.6) 2 (40)
Age (yr)
<55 - 11 (61.1) 1 (20)
≥55 2 (100)   7 (38.9) 4 (80)
Tumor site
Parotid gland -   2 (11.1) -
Submandibular gland - 1 (5.6) -
Sublingual gland - 1 (5.6) -
Palate 2 (100) 10 (55.6) 2 (40)
Upper lip - - -
Lower lip - - -
Tongue - 1 (5.6) -
Buccal - - 1 (20)
Retromolar area - - -
Floor of mouth -   3 (16.7) 2 (40)
Histology
Solid 2 (100)   5 (27.8) 2 (40)
Tubular and cribriform - 13 (72.2) 3 (60)
Perineural invasion 2 (100) 14 (77.8) 3 (60)
All patients 2 (100) 18 (100)   5 (100)
ACC, adenoid cystic carcinoma.
RESULTS
Characteristics of the patients 
The clinicopathological characteristics of the patients are listed 
in Table 1. The age range of the patients was 26−71 years; me-
dian age at diagnosis was 55 years. Among the 48 patients, 25 
(52.1%) were male; 26 (54.2%) were younger than 55 years old. 
Thirty-six tumors (75%) were found in minor salivary glands, 
and most of them (47.9%) were in the palate, followed by the 
submandibular gland (16.7%), floor of the mouth (12.5%), and 
parotid glands (6.3%). Histologically, 13 tumors (27.1%) were 
diagnosed as ACC solid type; 35 tumors (72.9%) were diagnosed 
as ACC tubular and cribriform type. perineural invasion was 
found in 29 cases (60.4%) of ACC samples. 
The median follow-up period for the patient population was 
5 years. During that time, local recurrence and distant metas-
tasis were identified in two (4.2%) and 18 (37.5%) of 48 patients, 
respectively. Five (10.4%) of the 48 patients died during follow-
up (Table 2). Of the deceased patients, four (80%) were older 
than 55 years, and all tumors were found in minor salivary 
glands: two of them were solid type, three of them had peri-
neural invasion, and four of them showed distant metastasis. 
Since the hallmarks of poor prognosis are solid histological 
type, perineural invasion, and distant metastasis,2 Kaplan-Meier 
analysis was performed to evaluate whether these factors af-
720
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fected prognosis. Histological type and perineural invasion 
were not significantly correlated with survival rate, whereas 
distant metastasis was found to be significantly correlated with 
poor survival (p=0.044) (Supplementary Fig. 1A-C, only on-
line).
Myb expression pattern in ACC
All 48 ACC patient samples were screened for Myb staining. 
Myb expression was not detected in nontumoral salivary gland 
parenchyma. Overall, 41 of 48 ACC samples (85.4%) were posi-
tively stained for Myb. Myb expression was detected in the 
nucleus and ranged from negative to strongly positive in in-
tensity. In tubular foci, positive signals were predominantly 
found in myoepithelial cells (Fig. 1). Myb expression did not 
significantly differ depending on the anatomic site of tumors 
or clinical features of the patients. However, Myb expression 
differed significantly based on the histological type of ACC 
(Table 1). Thirty-three cases of tubular and cribriform ACC 
(94.3%) showed Myb positivity, whereas eight cases of solid 
type ACC (61.5%) showed Myb positivity (p=0.011), according 
to Fisher’s exact test. Myb expression had no significant effect 
on survival rate when Kaplan-Meier analysis was performed 
(Supplementary Fig. 1D, only online). 
Relationship between ATM levels and patient 
outcomes in ACC
Antibody specificity was validated using human lymph node 
tissue as a positive control. For negative control, the entire pro-
cedure was conducted with the omission of ATM antibody (Fig. 
2A and B). For normal salivary glands, ATM protein was de-
tected in the nucleus of acinar and ductal cells (Fig. 2C). ATM 
expression was reduced/absent in cancer cells and stromal fi-
broblasts in 58.3% and 60.4% of patients, respectively, com-
pared with that in adjacent normal tissue (Fig. 2D-G). ATM lev-
els in cancer cells were negatively correlated with age (p= 





Fig. 1. Myb expression in ACC. (A) Negative control was obtained by the omission of Myb antibody in ACC. (B) Myb expression was not detected in 
non-tumoural salivary gland parenchyma. (C) Myb expression in ACC, solid type. Myb expression was detected in myoepithelial cells, but not in duc-
tal cells (indicated by the black arrow). (D) Myb expression in ACC, tubular and cribriform types. Original magnification of all figures: ×400. ACC, ade-
noid cystic carcinoma.
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ated with the loss of ATM expression in stromal fibroblasts 
(p=0.008), according to Fisher’s exact test, as shown in Table 3. 
Kaplan-Meier analysis revealed that low ATM expression in 
cancer cells was correlated with poor survival (p=0.037). Low 
ATM expression in stromal fibroblasts, however, was not sig-
nificantly related to patient survival (Fig. 3A and B). Further-
more, low ATM expression, either in cancer cells or stromal fi-
broblasts, was not significantly correlated with metastasis-free 
survival (Fig. 3C and D). 
Relationship among p53, phospho-p53 (S15), and 
patient outcomes in ACC
Of the 48 patients, 38 (79.2%) had p53 expression and 30 
(62.5%) had phospho-p53 (S15) expression (Fig. 4). No posi-
tive correlation was observed between the expression pat-
terns of these proteins and clinical findings, except for histo-
logical type, according to Fisher’s exact test (p=0.016) (Table 
3). Although statistical significance was not attained, positive 






Fig. 2. ATM expression in ACC. (A) Negative control was obtained by the omission of ATM antibody. (B) Positive control: ATM antibody-specific stain-
ing was performed in human lymph nodes. (C) ATM expression was observed in the nuclei of acinar and ductal cells in normal salivary glands. (D) 
ATM positivity in cancer cells and stromal fibroblasts. (E) ATM was positive in cancer cells and negative in stromal fibroblasts. (F) ATM was positive 
in stromal fibroblasts and negative in cancer cells. (G) ATM was negative in both cancer cells and stromal fibroblasts. Original magnification of all fig-
ures: ×200. Inset: original magnification ×1000. ATM, ataxia telangiectasia mutated; ACC, adenoid cystic carcinoma.
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showed tendencies of being correlated with poor survival rate 
(Fig. 5A and B). 
Upon analyzing ATM expression stratified by positive p53 
expression or negative phospho-p53 expression, loss of ATM 
and positive p53 expression significantly reduced overall sur-
vival (p=0.017) (Fig. 5C). Loss of ATM and negative phospho-
p53 expression was associated with worse prognosis, although 
statistical significance was not attained (Fig. 5D). In addition, 
loss of ATM, given positive p53 or negative phospho-p53 ex-
pression, reduced metastasis-free survival, although statistical 
significance was not attained (Supplementary Fig. 2, only on-
line). As shown in Table 3, all five deceased patients exhibited 
a loss of ATM expression, as well as positive p53 and negative 
phospho-p53 expression, confirming that these markers can 
predict poor prognosis in ACC patients. 
DISCUSSION
ATM is activated within seconds to minutes upon exposure to 
ionizing radiation and can phosphorylate various downstream 
substrates, some of which play crucial roles in regulating cell 
cycle arrest, DNA repair, and apoptosis.20 To illustrate, ATM is 
an upstream regulator of p53, a well-known tumor suppres-
sor: ATM modulates progression of the cell cycle and apopto-
sis via activation and stabilization of p53.21 In response to ion-
izing radiation, the kinase activity of ATM is enhanced, leading 
to phosphorylation of p53 on serine 15 and activation of the 
Table 3. Relationships among ATM, p53, and Phospho-p53 (S15) Expressions and Patient Outcomes in ACC
Parameter
No. of patients ATM loss in cancer ATM loss in stroma
Positive expression of 
p53 expression
Positive expression of 
phospho-p53 (S15)
n (%) n (%) n (%) n (%) n (%)
Sex
Woman 23 (47.9) 15 (65.2) 16 (69.6) 16 (69.6) 9 (39.1)
Man 25 (52.1) 13 (52) 13 (52) 22 (88) 9 (36)
p value 0.263 0.172 0.112 0.529
Age (years old)
<55 26 (54.2) 10 (38.5) 14 (53.8) 21 (80.8) 9 (34.6)
≥55 22 (45.8) 18 (81.8) 15 (68.2) 17 (77.3) 9 (40.9)
p value 0.003 0.238 0.521 0.440
Tumor site
Parotid gland   3 (6.3)   1 (33.3) 2 (66.7) 3 100) 0 (0)
Submandibular gland   8 (16.7)   4 (50) 5 (62.5) 6 (75) 6 (75)
Sublingual gland   1 (2.1)   1 (100) 1 (100) 1 (100) 1 (100)
Palate 23 (47.9) 14 (60.9) 15 (65.2) 17 (73.9) 8 (34.8)
Upper lip   2 (4.2)   1 (50) 1 (50) 2 100) 1 (50)
Lower lip   1 (2.1)   0 (0) 0 (0) 1 100) 0 (0)
Tongue   2 (4.2)   2 (100) 1 (50) 2 100) 0 (0)
Buccal   1 (2.1)   0 (0) 0 (0) 1 100) 0 (0)
Retromolar area   1 (2.1)   0 (0) 0 (0) 1 100) 0 (0)
Floor of mouth   6 (12.5)   5 (83.3) 4 (66.7) 4 (66.7) 2 (33.3)
p value 0.475 0.863 0.992 0.219
Histology
Solid 13 (27.1) 10 (76.9) 8 (61.5) 7 (53.8) 4 (30.8)
Tubular and cribriform 35 (72.9) 18 (51.4) 21 (60) 31 (88.6) 14 (40)
p value 0.102 0.597 0.016 0.406
Perineural invasion 29 (60.4) 17 (58.6) 22 (75.9) 23 (79.3) 11 (37.9)
 0.597 0.008 0.624 0.592
Distant metastasis 18 (37.5) 13 (72.2) 14 (77.8) 13 (72.2) 6 (33.3)
0.113 0.053 0.287 0.442
Death due to ACC   5 (11.6)   5 (100) 3 (60) 5 (100) 0 (0)
0.057 0.667 0.293 0.083
Total patients 48 (100) 28 (58.3) 29 (60.4) 38 (79.2) 18 (37.5)
ATM, ataxia telangiectasia mutated; ACC, adenoid cystic carcinoma.
p values from Fisher’s exact test are provided.
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checkpoint kinase Chk2, which, in turn, phosphorylates p53 
on serine 20. These interactions result in stabilization and ac-
tivation of p53:22,23 serine 15, threonine 18, and serine 20, being 
key phosphorylation sites of p53, are involved not only in stim-
ulating p53’s interaction with the transcriptional machinery 
but also in inhibiting MDM-mediated repression of p53.24 
Mutated p53 is often characterized by increased half-life, as 
it inhibits its own degradation by the ubiquitin complex.25 
Therefore, the level of p53 can be modulated both by the ATM-
dependent pathway and the mutational status of p53 itself. 
The mutational status of p53 itself is an independent unfavor-
able prognostic marker in many malignancies.14 In terms of 
ACC, patients with p53-positive expression had a greater chance 
of developing metastasis, as well as poorer 5-year overall sur-
vival.26 In our study, positive p53 expression showed a tendency 
of being correlated with poor survival, even though statistical 
significance was not attained.
This study focused on investigating whether the expression 
patterns of ATM and p53 and its ATM-mediated phosphory-
lated form are associated with patient survival. The prognostic 
role of ATM and p53 has previously been demonstrated in hu-
man malignancies, including breast,22 pancreas,12 lung,16 and 
stomach cancer,27 but data thereof in ACC are lacking. All these 
studies have shown that ATM expression, either independently 
or in combination with p53 expression, is correlated with pa-
tient outcome. In our study, loss of ATM expression in ACC can-
cer cells was significantly associated with reduced patient sur-
vival. In addition, p53-positive expression or phospho-p53 (S15)-
negative expression was weakly correlated with poor survival. 
Interestingly, combined analysis of ATM and p53 had better 
predictability than individual analysis of each protein. Given 
positive p53 or negative phospho-p53 (S15) expression, loss of 
ATM was associated with worse survival. The loss or reduced 
expression of ATM may render cells susceptible to irreversible 
DNA damage and subsequent cancerization, ultimately facili-
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Fig. 3. Overall survival rates according to ATM expression in cancer cells (A) and stromal fibroblasts (B). Metastasis-free survival rates according to 
ATM expression in cancer cells (C) and stromal fibroblasts (D). ATM, ataxia telangiectasia mutated; ACC, adenoid cystic carcinoma.
ACC specific survival by ATM expression in cancer cells
Metastasis free survival by ATM expression in cancer cells
ACC specific survival by ATM expression in stromal fibroblasts
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ation and proliferation.28 
Several researchers have retrospectively studied the clinico-
pathological features of ACC, attempting to identify significant 
prognostic factors; however, findings remain controversial. 
Solid histological type and perineural invasion have been con-
sidered as important indicators of poor prognosis in ACC pa-
tients.2 In particular, the presence of perineural invasion can 
result in higher rates of recurrence.29,30 In our study, however, 
the prognostic value of perineural invasion was not signifi-
cant, possibly due to a small sample size limited to minor sali-
vary glands and relatively short follow-up period. 
Of note, ATM loss in stroma was strongly correlated with 
perineural invasion in our study, even though ATM loss in 
stroma was not correlated with patient survival. As ATM loss 
in stroma can serve as an independent prognostic marker in 
early stage breast cancer,11 further study needs to be conduct-
ed to unravel the mechanism underlying the association be-
tween the loss of ATM in stromal fibroblasts and perineural 
invasion.
In accordance with previous studies, Myb-NFIB fusion was 
not expressed in non-ACC neoplasms of the head and neck, 
confirming the high specificity of Myb-NFIB fusion for ACC.4 
All 48 ACC patient samples were screened for Myb staining: 
85.4% were positively stained for Myb, whereas Myb staining 
was negative in nontumoral salivary gland parenchyma. Myb 
expression was not significantly associated with patient sur-
vival, confirming that Myb is a suitable diagnostic marker for 
ACC, but not a prognostic marker.
Taken together, expression levels of ATM in cancer cells 
alone or in combination with positive p53 expression hold 
strong prognostic value for predicting the overall survival of 
ACC patients, and thus could serve as promising biomarkers 
to assess patient outcomes. Prognostic values of well-known 
clinical factors, perineural invasion, and histological types 
were not evident in this study, possibly due to small sample 
size and relatively short follow-up period. Additional studies 
with a larger sample are warranted. 
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Fig. 4. Expression of p53 and phospho-p53 (S15) in adenoid cystic carcinoma. Positive expression of p53 (A) and negative expression of p53 (B). Posi-
tive expression of phospho-p53 (S15) (C) and negative expression of phospho-p53 (S15) (D). Original magnification of all figures: ×200. Inset: original 
magnification ×1000.
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Fig. 5. Overall survival rates of ACC patients according to the expression of p53, phospho-p53 (S15), ATM given positive p53 expression, and ATM giv-
en negative phospho-p53 (S15) expression. (A) Overall survival according to p53 expression. (B) Overall survival according to phospho-p53 (S15) ex-
pression. (C) Overall survival according to the expression of ATM given positive p53 expression. (D) Overall survival according to the expression of 
ATM given negative phospho-p53 (S15) expression. ATM, ataxia telangiectasia mutated; ACC, adenoid cystic carcinoma.
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